Why is Athersys suddenly hyping its preclinical obesity drug?

Featured Story

Why is Athersys suddenly hyping its preclinical obesity drug?

May 23, 2012 9:19 am by | 0 Comments

It isn’t easy to get profit-hungry Wall Street excited about a drug that hasn’t yet been tested in humans and is at best years and years away from generating any…


Stem cell company Athersys eyes potential new opportunities for its stroke therapy in Japan

Stem cell company Athersys eyes potential new opportunities for its stroke therapy in Japan

March 14, 2014 10:09 am by | 0 Comments

Athersys (NYSE:ATHX) is looking to Japan for potential opportunities to bring its MultiStem therapies to market quicker. In its annual financial results call on Thursday, Athersys’ chief operating officer, BJ…


Stem cell firm Athersys faces enrollment struggles with one Phase 2 study; readies to begin another

Stem cell firm Athersys faces enrollment struggles with one Phase 2 study; readies to begin another

August 14, 2013 6:00 am by | 1 Comments

Thanks in part to a SBIR Fast Track grant worth up to $2.8 million, stem cell company Athersys (Nasdaq: ATHX) is gearing up to advance its third MultiStem program into…



Stem cell company Athersys expects more R&D spending, potential partnerships in 2013

Stem cell company Athersys expects more R&D spending, potential partnerships in 2013

March 13, 2013 10:16 am by | 1 Comments

Cleveland-based Athersys (NYSE:ATHX) has a full plate as it continues to advance its “off the shelf” stem cell therapy, MultiStem, through clinical trials in several indications. That means shareholders can…


Athersys-Pfizer IBD phase 2 trial to wrap up by end of the year

Athersys-Pfizer IBD phase 2 trial to wrap up by end of the year

May 14, 2012 5:42 pm by | 0 Comments

Stem cell therapeutics developer Athersys’ (NASDAQ:ATHX) phase 2 clinical study investigating the treatment of inflammatory bowel disease with partner Pfizer (NYSE:PFE) is expected to complete patient enrollment by the end…


Athersys touts stem cell technology as treatment for rare Hurler’s syndrome

Athersys touts stem cell technology as treatment for rare Hurler’s syndrome

April 20, 2012 10:02 am by | 0 Comments

Results of a preclinical study suggest that stem cell technology fromĀ  Athersys (NASDAQ:ATHX) could offer a treatment for patients suffering from a rare disorder called “Hurler’s syndrome.” Hurler’s syndrome is…


Athersys awarded stem cell patent for graft-versus-host disease

Athersys awarded stem cell patent for graft-versus-host disease

April 4, 2012 9:28 am by | 0 Comments

Stem cell developer Athersys (NASDAQ:ATHX) has received a U.S patent that covers the use of nonembryonic, multipotent stem cells in the treatment of graft-versus-host disease. Graft-versus-host disease (GvHD) often occurs…


Athersys CEO: Stroke therapy could be one of biggest blockbusters ever

Athersys CEO: Stroke therapy could be one of biggest blockbusters ever

April 2, 2012 10:36 am by | 2 Comments

Gil Van Bokkelen, CEO of stem cell company Athersys (NASDAQ:ATHX), is typically one to speak in cautious and measured tones, but he made a brash statement in the company’s most…



Athersys gets OK for German solid organ transplant clinical trial

Athersys gets OK for German solid organ transplant clinical trial

March 27, 2012 5:40 pm by | 0 Comments

Stem cell developer Athersys (NASDAQ:ATHX) has received German regulatory clearance for a physician-sponsored solid organ transplant clinical trial. The study will enroll up to 24 patients and examine Athersys’ MultiStem…


Stem cell company Athersys secures $9M in private stock sale

Stem cell company Athersys secures $9M in private stock sale

March 9, 2012 11:38 am by | 0 Comments

Stem cell developer Athersys (NASDAQ:ATHX) has secured $9 million in a private placement with an unidentified investor. Cleveland-based Athersys said it would issue about 4.3 million shares of common stock…


Athersys, University Hospitals partner for clinical trials of MultiStem for stroke

Athersys, University Hospitals partner for clinical trials of MultiStem for stroke

February 22, 2012 2:12 pm by | 0 Comments

University Hospitals Case Medical Center will be one of 25 institutions in the U.S. to take part in a phase 2 clinical trial of a stem cell treatment for stroke…


Athersys touts results of phase 1 blood diseases trial

Athersys touts results of phase 1 blood diseases trial

February 1, 2012 3:38 pm by | 0 Comments

Stem cell therapy developer Athersys (NASDAQ:ATHX) reported positive results from a phase 1 clinical trial in patients with leukemia and similar blood diseases. The trial showed that the company’s MultiStem…


Stem cell company Athersys gets grant to study traumatic brain injury

Stem cell company Athersys gets grant to study traumatic brain injury

February 1, 2012 11:00 am by | 0 Comments

Stem cell developer Athersys (NASDAQ:ATHX) has received $3.6 million in new grant funding, with one of the grants going toward studying its MultiStem technology for the treatment of traumatic brain…


Athersys gets U.S. stem cell patent for heart attack, other conditions

Athersys gets U.S. stem cell patent for heart attack, other conditions

January 4, 2012 9:17 am by | 0 Comments

Athersys (NASDAQ:ATHX) has obtained a U.S. patent that covers the use of nonembryonic multi-potent stem cells for the treatment of several heart conditions, including heart attack. The patent provides protection…


Athersys closes $20 million stock purchase deal with Aspire Capital

Athersys closes $20 million stock purchase deal with Aspire Capital

November 14, 2011 3:28 pm by | 0 Comments

A new common stock purchase agreement with Aspire Capital Fund LLC will give Cleveland biopharmaceutical company Athersys (NASDAQ:ATHX) up to $20 million in investment dollars. Chicago-based Aspire has committed to…


Athersys to investigate stem cell treatment for multiple sclerosis

Athersys to investigate stem cell treatment for multiple sclerosis

October 21, 2011 8:16 am by | 0 Comments

Athersys (Nasdaq:ATHX) has entered a partnership with a nonprofit multiple sclerosis group to investigate its adult stem cell technology for the treatment of MS. Fast Forward, a nonprofit subsidiary of…